Your session is about to expire
← Back to Search
BLU-222 for Solid Cancers
Study Summary
This trial is testing a new cancer drug to see if it is safe and works well against cancer cells.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My endometrial or gastric cancer has worsened after 2 treatments, including a platinum-based therapy.I don't have lasting side effects from previous treatments.My cancer has worsened despite standard treatments.My breast cancer is HR+ HER2- and worsened after CDK4/6 inhibitor treatment.My ovarian cancer is not responding to platinum-based treatments and has a specific genetic feature.I do not have serious heart problems like recent heart attacks or uncontrolled high blood pressure.I do not have any major surgeries planned within 2 weeks of starting the study drug.My cancer has spread to my internal organs, lymph system, or brain/spinal cord linings.I have a known bleeding disorder or brain hemorrhage.I have an active lung condition not caused by cancer within the last 28 days.I am not postmenopausal or surgically sterile and will not use or cannot use effective birth control.You have a history of heart rhythm issues or a family history of heart rhythm issues.I have been treated with specific cancer drugs before, except for a few allowed in early trial phases.I am willing and able to follow the study's schedule and procedures.I have had cancer other than in situ carcinomas that needed treatment within the last 2 years.My cancer has spread to my brain or spinal cord, causing worsening symptoms or needing more steroids.I do not have any active, uncontrolled infections like TB, hepatitis, AIDS, or COVID-19.I am not taking any medication or herbal remedy that can't be stopped 2 weeks before starting the study drug.
- Group 1: BLU-222 Monotherapy
- Group 2: BLU-222 + Carboplatin
- Group 3: BLU-222 + Ribociclib + Fulvestrant
- Group 4: BLU-222 + Fulvestrant
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
How many healthcare facilities are presently conducting this trial?
"Subjects for this medical trial can be recruited from MD Anderson Cancer Center in Houston, Texas, Columbia University Herbert Irving Comprehensive Cancer Center in New york City and Florida Cancer Specialists in Sarasota, FL. Moreover, there are 5 other recruitment sites associated with the project."
Are there any vacancies available for individuals to partake in this research?
"Affirmative. According to clinicaltrials.gov, this medical trial began recruiting patients on April 7th 2022 and was last updated November 21st of the same year. The study requires 366 participants from 5 different sites for enrollment."
How many participants are permitted to enroll in this experiment?
"This medical trial necessitates a population of 366 individuals who meet the given criteria for participation. Patients have the option to join from two major sites, including MD Anderson Cancer Center in Houston and Columbia University Herbert Irving Comprehensive Cancer Centre in New york City."
Share this study with friends
Copy Link
Messenger